SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001047469-18-002332
Filing Date
2018-03-29
Accepted
2018-03-29 15:40:37
Documents
18
Effectiveness Date
2018-03-29

Document Format Files

Seq Description Document Type Size
1 DEFM14A a2235143zdefm14a.htm DEFM14A 3238476
2 G864942.JPG g864942.jpg GRAPHIC 11974
3 G513347.JPG g513347.jpg GRAPHIC 10443
4 G943258.JPG g943258.jpg GRAPHIC 2617
5 G107001.JPG g107001.jpg GRAPHIC 4019
6 G52164.JPG g52164.jpg GRAPHIC 12642
7 G908249.JPG g908249.jpg GRAPHIC 12781
8 G28407.JPG g28407.jpg GRAPHIC 8245
9 G378180.JPG g378180.jpg GRAPHIC 7600
10 G20163.JPG g20163.jpg GRAPHIC 6245
11 G153945.JPG g153945.jpg GRAPHIC 7887
12 G670656.JPG g670656.jpg GRAPHIC 4947
13 G872080.JPG g872080.jpg GRAPHIC 23806
14 G165903.JPG g165903.jpg GRAPHIC 35520
15 G748835.JPG g748835.jpg GRAPHIC 20469
16 G824325.JPG g824325.jpg GRAPHIC 6109
17 G63678BGI001.GIF g63678bgi001.gif GRAPHIC 170518
18 G63678BGI002.GIF g63678bgi002.gif GRAPHIC 120948
  Complete submission text file 0001047469-18-002332.txt   3884541
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 000-23186 | Film No.: 18722782
SIC: 2836 Biological Products, (No Diagnostic Substances)